This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. center for biologics evaluation and research (CBER), center for drug evaluation and research (CDER). April 1996
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. emea/chmp/bwp/49348/2005
Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process non-clinical and clinical issues. emea/chmp/bmwp/101695/2006
ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process
Looby M, Ibarra N, Pierce J, Buckley K, O’Donovan E, Heenan M, Moran E, Farid S, Baganz, F (2011) Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnol Prog 27(6):1718–1729
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Moran, E., Gammell, P. (2013). Lifecycle Management for Recombinant Protein Production Using Mammalian Cell Culture Technology. In: Zhou, W., Kantardjieff, A. (eds) Mammalian Cell Cultures for Biologics Manufacturing. Advances in Biochemical Engineering/Biotechnology, vol 139. Springer, Berlin, Heidelberg. https://doi.org/10.1007/10_2013_258
Download citation
DOI: https://doi.org/10.1007/10_2013_258
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54049-3
Online ISBN: 978-3-642-54050-9
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)